May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Utilities for quality of life from time trade–off and conjoint analysis in age related macular degeneration
Author Affiliations & Notes
  • A.R. Hill
    Sch Built Enviro, Heriot–Watt Univ, Edinburgh, United Kingdom
  • P. Aspinall
    Sch Built Enviro, Heriot–Watt Univ, Edinburgh, United Kingdom
  • B. Dhillon
    Ophthalmology, Princess Alexandra Eye Pavilion, Edinburgh, United Kingdom
  • A. Armbrecht
    Ophthalmology, Princess Alexandra Eye Pavilion, Edinburgh, United Kingdom
  • C. Lumsden
    Ophthalmology, Princess Alexandra Eye Pavilion, Edinburgh, United Kingdom
  • P. Nelson
    Sch Built Enviro, Heriot–Watt Univ, Edinburgh, United Kingdom
  • R. Brice
    Adelphi Research, Bollington, United Kingdom
  • A. Vickers
    Adelphi Research, Bollington, United Kingdom
  • P. Buchholz
    Allergan Ltd, Hamburg, Germany
  • Footnotes
    Commercial Relationships  A.R. Hill, Allergan Ltd R; P. Aspinall, Allergan Ltd F; B. Dhillon, Allergan Ltd F; A. Armbrecht, None; C. Lumsden, None; P. Nelson, None; R. Brice, Adelphi Research I; A. Vickers, Adelphi Research E; P. Buchholz, Allergan Ltd E.
  • Footnotes
    Support  Allergan Ltd
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3080. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A.R. Hill, P. Aspinall, B. Dhillon, A. Armbrecht, C. Lumsden, P. Nelson, R. Brice, A. Vickers, P. Buchholz; Utilities for quality of life from time trade–off and conjoint analysis in age related macular degeneration . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3080.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To determine utilities and the relative importance of different daily tasks affecting vision related quality of life (QoL) in patients with age related macular degeneration (AMD). Methods:Several tests were given to 120 patients attending an AMD clinic including visual function measures, the NEI–VFQ25 QoL questionnaire, an impact of disease questionnaire (IoD), a conjoint analysis task (CA) to assess patient values and relative importance of daily tasks, and time trade–off (TTO) utility judgements determined as a proportion (P) of the respondent's estimate of their remaining expected life years. AMD was categorised into a binocular status of 'mild', 'moderate' and 'severe' based on the international classification and grading system. Results:Patients mean age = 77.8 yrs (SD 6.7), mean binocular best corrected distance logMAR acuity = 0.50 (SD 0.42), mean binocular near acuity = 0.69 (SD 0.43), and mean contrast sensitivity (Pelli–Robson) = 1.19 (SD 0.35). Using binocular AMD status 15% of patients were classified as ‘mild’, 32% as ‘moderate’ and 53% as ‘severe’. Principal component analysis of the CA utilities showed relative independence of the attributes used in the conjoint task but there was a complex factor structure relating to the levels of difficulty associated with each attribute. TTO utilities (1–P) for remaining life were 0.96 for 'mild', 0.92 for 'moderate' and 0.71 for 'severe' AMD. CA showed that problems of greatest importance were outdoor mobility and reading ability, while the ability to recognise faces and problems from glare were rated as least important. QoL and IoD questionnaires showed that all stages of the disease had a significant impact on emotional factors but the most significant effects on the ability to perform daily tasks occurred between the ‘moderate’ to ‘severe’ forms of the disease. Conclusions: CA suggested preference for preserving an independent life–style, while QoL questionnaires showed that, except for emotional factors, the most significant effects on daily activities occurred between ‘moderate’ and ‘severe’ AMD. Utilities, expressed in terms of estimated remaining life years from TTO, also showed that the greatest change occurred between 'moderate' to 'severe' AMD. Commercial relationship: The research was supported by Allergan Limited.

Keywords: age–related macular degeneration • quality of life 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×